| 5.095 0.225 (4.62%) | 05-07 11:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.9 | 1-year : | 6.89 |
| Resists | First : | 5.05 | Second : | 5.9 |
| Pivot price | 4.3  |
|||
| Supports | First : | 4.01 | Second : | 3.36 |
| MAs | MA(5) : | 4.57 |
MA(20) : | 4.21 |
| MA(100) : | 2.97 |
MA(250) : | 5.61  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 78.5 |
D(3) : | 68.6 |
| RSI | RSI(14): 65.7 | |||
| 52-week | High : | 13.39 | Low : | 2.06 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ICU ] has closed below upper band by 4.3%. Bollinger Bands are 20.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.06 - 5.08 | 5.08 - 5.1 |
| Low: | 4.34 - 4.36 | 4.36 - 4.37 |
| Close: | 4.84 - 4.87 | 4.87 - 4.9 |
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Thu, 07 May 2026
[S-1/A] SeaStar Medical Holding Corp Amends IPO Registration Statement - Stock Titan
Wed, 06 May 2026
SeaStar Medical Holding Corporation to Announce First Quarter Financial Results on May 13, 2026 - Quiver Quantitative
Wed, 06 May 2026
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026 - GlobeNewswire
Wed, 06 May 2026
[EFFECT] SeaStar Medical Holding Corp SEC Filing - Stock Titan
Wed, 29 Apr 2026
SeaStar Medical (NASDAQ: ICU) seeks approval to expand 2022 equity incentive plan - Stock Titan
Tue, 28 Apr 2026
Securities class action against SeaStar Medical (NASDAQ: ICU) dismissed with prejudice - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 159 (K) |
| Shares Short P.Month | 168 (K) |
| EPS | -5.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.71 |
| Profit Margin | 0 % |
| Operating Margin | -718.1 % |
| Return on Assets (ttm) | -80.9 % |
| Return on Equity (ttm) | -295.2 % |
| Qtrly Rev. Growth | 526.9 % |
| Gross Profit (p.s.) | 0.29 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.84 |
| PEG Ratio | 0 |
| Price to Book value | 1.79 |
| Price to Sales | 15.83 |
| Price to Cash Flow | -1.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|